Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI study of Bemnifosbuvir/Ruzasvir and Biktarvy
NCT06356194Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Apr 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bemnifosbuvir and ruzasvir in hepatitis C (HCV) (2 arms), sponsored by Atea Pharmaceuticals. Primary endpoints: Pharmacokinetics of Bemnifosbuvir (BEM) and Ruzasvir (RZR) and Pharmacokinetics of Biktarvy (BIK). Started Apr 2024; status: completed.
02
Drugs
bemnifosbuvirruzasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT06356194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06356194.